Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

In this online program experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.

Share

Program Content

No activities added yet

Activities

Next-Gen BTK Inhibitors
Next-Generation BTK Inhibitors and Why We Need Them
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2019

Expires: October 22, 2020

BTK Inhibitor FAQs
Frequently Asked Questions About BTK Inhibitor Use in B-Cell Malignancies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 21, 2020

Expires: February 19, 2021

Zanubrutinib in MCL
Meet Zanubrutinib, the Newest Bruton’s Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2020

Expires: March 23, 2021

Activities

BTKi Safety
BTK Inhibitors for Managing Patients with B-Cell Malignancies: Safety and Optimal Use
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in MCL
Practical Case Discussions: BTK inhibitor Therapy for MCL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in Frontline CLL
Practical Case Discussions: BTK inhibitor Therapy for Frontline CLL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in Other Types
BTK Inhibitors in “Other” B-Cell Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi Resistance
Overcoming BTK Inhibitor Resistance and Combination Strategies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly